  <p> <strong><u>Release Date</u></strong><br>
    10 December 2014<br>
    <br>
    <strong><u>Expiration Date</u></strong><br>
    10 December 2015<br>
    <br>
    <strong><u>Faculty</u></strong><br>
    Clare Scott, MBBS, PhD, <br>
    The Walter and Eliza Hall Institute of Medical Research, <br>
    Melbourne, Australia</p>
 
Jonathan Ledermann, MD, FRCP, UCL <br>
Cancer Institute University College London, <br>
London, United Kingdom
<br>
<br>
Amit Oza, MD, FRCPC, MBBS, <br>
  Princess Margaret Hospital University of Toronto,                                  <br>
  Toronto, Ontario, Canada<br>
    <br>
    <strong><u>Target Audience</u></strong><br>
    This activity is intended for medical oncologists, gynecologic  oncologists, and other healthcare professionals involved in the treatment of  patients with advanced ovarian cancer.</p>
<p><strong><u>Learning Objectives</u></strong><br>
After successful completion of this educational activity, participants  should be able to:</p>
<ul class="bullets">
  <li>Review the current  recommendations for genetic testing for patients diagnosed with ovarian cancer </li>
  <li>Evaluate prognosis of  patients with <em>BRCA1</em> and <em>BRCA2</em> mutations and identify&nbsp;the role  of PARP inhibition as a potential emerging targeted therapy </li>
  <li>Examine recent data and  ongoing trials of maintenance therapy in ovarian cancer, including patient  selection for targeted therapy based on available biomarkers</li>
  <li>Describe&nbsp; current  and promising treatment options for relapsed  platinum-sensitive ovarian cancer </li>
</ul>
<br>
  <strong><u>Method of Participation</u></strong><br>
  <p>There are no fees for participating in and receiving CME credit for    this activity. In order to receive credit, participants must   successfully  complete the online posttest and activity evaluation. Your   participation in  this CME activity will be recorded in prIME   Oncology's database. However, upon  request, your CME credit certificate   will be emailed to you. <br>
    <br>
    Technical  requirements may be found under the <a href="http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx">Terms of  Use.</a></p>
  <p>Links to the posttest are available on the video player pages.</p>
  <p>In order to receive credit, participants must successfully complete the  online posttest with 75% or higher.</p>
  <strong><u>Provider</u></strong><br>
  This activity is provided by prIME Oncology.<br>
  <br>
  <strong><u>Support</u></strong><br>
<p>This educational activity is supported by AstraZeneca.</p>
<strong><u>Continuing Medical Education</u></strong><br>
  <p>prIME Oncology is accredited by the Accreditation Council for   Continuing Medical Education (ACCME®) to provide continuing medical   education for physicians.</p>
  <p>prIME Oncology designates this enduring activity for a maximum of <em>1 AMA PRA Category 1 Credit</em>™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.<br>
    <br>
    <strong><u>Disclosure Regarding Unlabeled Use</u></strong><br>
  This activity  may contain discussion of published and/or   investigational uses of agents that  are not indicated by the US Food   and Drug Administration or European Medicines  Agency. Please refer to   the official prescribing information for each product  discussed for   discussions of approved indications, contraindications, and  warnings.</p>
  <p><strong><u>Disclaimer</u></strong><br>
    Participants  have an implied responsibility to use the newly acquired   information to enhance  patient outcomes and their own professional   development. The information  presented in this activity is not meant to   serve as a guideline for patient  management. Any procedures,   medications, or other courses of diagnosis or  treatment discussed or   suggested in this activity should not be used by  clinicians without   evaluation of their patients&rsquo; conditions and possible  contraindications   or dangers in use, review of any applicable manufacturer&rsquo;s product    information, and comparison with recommendations of other authorities. </p>

